HRP20180323T8 - Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja - Google Patents

Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja

Info

Publication number
HRP20180323T8
HRP20180323T8 HRP20180323TT HRP20180323T HRP20180323T8 HR P20180323 T8 HRP20180323 T8 HR P20180323T8 HR P20180323T T HRP20180323T T HR P20180323TT HR P20180323 T HRP20180323 T HR P20180323T HR P20180323 T8 HRP20180323 T8 HR P20180323T8
Authority
HR
Croatia
Prior art keywords
authistic
chromon
spectra
disorders
derivative
Prior art date
Application number
HRP20180323TT
Other languages
English (en)
Croatian (hr)
Inventor
Agnès AUCLAIR
Paul Moser
Pierre Sokoloff
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of HRP20180323T1 publication Critical patent/HRP20180323T1/hr
Publication of HRP20180323T8 publication Critical patent/HRP20180323T8/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20180323TT 2013-12-13 2014-12-12 Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja HRP20180323T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder
EP14812465.4A EP3079688B1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder

Publications (2)

Publication Number Publication Date
HRP20180323T1 HRP20180323T1 (hr) 2018-04-06
HRP20180323T8 true HRP20180323T8 (hr) 2019-01-25

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180323TT HRP20180323T8 (hr) 2013-12-13 2014-12-12 Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja

Country Status (29)

Country Link
US (1) US10028948B2 (enExample)
EP (1) EP3079688B1 (enExample)
JP (1) JP6419826B2 (enExample)
KR (1) KR102280530B1 (enExample)
CN (1) CN105792824B (enExample)
AU (1) AU2014363428B2 (enExample)
BR (1) BR112016012552A8 (enExample)
CA (1) CA2932791C (enExample)
CY (1) CY1119907T1 (enExample)
DK (1) DK3079688T3 (enExample)
ES (1) ES2657706T3 (enExample)
HR (1) HRP20180323T8 (enExample)
HU (1) HUE036035T2 (enExample)
IL (1) IL245996B (enExample)
LT (1) LT3079688T (enExample)
MA (1) MA39076A1 (enExample)
MX (1) MX372922B (enExample)
MY (1) MY172937A (enExample)
NO (1) NO3079688T3 (enExample)
NZ (1) NZ720868A (enExample)
PL (1) PL3079688T3 (enExample)
PT (1) PT3079688T (enExample)
RS (1) RS56931B1 (enExample)
RU (2) RU2019104946A (enExample)
SA (1) SA516371298B1 (enExample)
SI (1) SI3079688T1 (enExample)
TN (1) TN2016000213A1 (enExample)
UA (1) UA117271C2 (enExample)
WO (1) WO2015086836A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2021048544A1 (en) * 2019-09-11 2021-03-18 Oxford Biodynamics Limited Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
PE20001088A1 (es) * 1998-10-08 2000-12-02 Smithkline Beecham Plc Compuestos derivados de tetrahidrobenzazepina
ES2367868T3 (es) * 2004-09-20 2011-11-10 Mount Sinai School Of Medicine Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR101921772B1 (ko) * 2011-05-13 2018-11-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
FR2976179A1 (fr) 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
CN105792824A (zh) 2016-07-20
CY1119907T1 (el) 2018-06-27
HRP20180323T1 (hr) 2018-04-06
JP6419826B2 (ja) 2018-11-07
EP3079688A1 (en) 2016-10-19
AU2014363428A1 (en) 2016-06-23
HK1223563A1 (zh) 2017-08-04
WO2015086836A1 (en) 2015-06-18
TN2016000213A1 (en) 2017-10-06
RU2686110C1 (ru) 2019-04-24
BR112016012552A8 (pt) 2022-11-08
KR102280530B1 (ko) 2021-07-21
KR20160088886A (ko) 2016-07-26
DK3079688T3 (da) 2018-01-29
JP2016540000A (ja) 2016-12-22
SA516371298B1 (ar) 2018-06-07
NZ720868A (en) 2022-04-29
SI3079688T1 (en) 2018-03-30
IL245996B (en) 2018-11-29
IL245996A0 (en) 2016-07-31
CA2932791A1 (en) 2015-06-18
AU2014363428B2 (en) 2019-09-12
MX372922B (es) 2020-04-27
CN105792824B (zh) 2018-08-03
PL3079688T3 (pl) 2018-05-30
RS56931B1 (sr) 2018-05-31
US20160303117A1 (en) 2016-10-20
UA117271C2 (uk) 2018-07-10
MY172937A (en) 2019-12-16
US10028948B2 (en) 2018-07-24
RU2019104946A (ru) 2019-04-01
ES2657706T3 (es) 2018-03-06
NO3079688T3 (enExample) 2018-04-21
MA39076A1 (fr) 2017-05-31
EP3079688B1 (en) 2017-11-22
HUE036035T2 (hu) 2018-06-28
MX2016007612A (es) 2016-09-09
CA2932791C (en) 2021-11-09
LT3079688T (lt) 2018-02-12
PT3079688T (pt) 2018-02-28

Similar Documents

Publication Publication Date Title
IL285971A (en) Pyrimidinedione compounds against cardiac conditions
DK3517538T3 (da) Pyrazolopyridin-derivat med GLP-1-receptoragonistvirkning
IL247841A0 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
HRP20190440T1 (hr) Uređaj za stimuliranje
HRP20180900T1 (hr) Heterociklički amidi kao inhibitori kinaza
IL242183B (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of their use
HUE036750T2 (hu) Alfa-v-béta-6 integrin antagonistákként alkalmazható naftiridin-származékok
HUE056428T2 (hu) Kristályos alakú difenilmetán-származék
LT3384749T (lt) Sėklų tiekimo aparatas
HRP20181339T1 (hr) Makrociklusi sa heterocikličkim p2' grupama kao inhibitori faktora xia
HRP20181429T8 (hr) Novi derivati benzimidazola kao inhibitori kinaze
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
SI2968269T1 (sl) Postopek priprave antagonistov beta 3 in vmesnih spojin
HRP20181650T1 (hr) Biciklički heterociklički derivati kao inhibitori bromodomene
LT3038650T (lt) Antikūnai ir foliatų receptoriaus 1 nustatymo testai
BR302013004392S1 (pt) Configuração aplicada emmetal sanitário
EP3020707A4 (en) P2X4 RECEPTOR ANTAGONIST
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
DK2938790T3 (da) Wc-tilbehør med bruseindretning
HRP20180323T8 (hr) Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja
HRP20150974T1 (xx) Derivati 2-amino-3-(imidazol-2-il)-piridin-4-ona i njihova uporaba kao inhibitora vegf receptora kinaze
PL3019242T3 (pl) Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B
GB201321089D0 (en) Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
GB201306587D0 (en) Adjustable probe
LT3233825T (lt) Diarilmetilideno piperidino dariniai ir jų naudojimas kaip delta opioidinių receptorių agonistų